Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,069
  • Shares Outstanding, K 5,894
  • Annual Sales, $ 10,020 K
  • Annual Income, $ -47,410 K
  • 60-Month Beta 3.76
  • Price/Sales 5.93
  • Price/Cash Flow N/A
  • Price/Book 3.25
Trade CRIS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.94
  • Number of Estimates 3
  • High Estimate -1.64
  • Low Estimate -2.10
  • Prior Year -2.40
  • Growth Rate Est. (year over year) +19.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.70 +12.06%
on 03/05/24
11.07 -1.79%
on 03/22/24
+1.10 (+11.26%)
since 02/28/24
3-Month
8.24 +31.92%
on 02/05/24
14.57 -25.41%
on 01/04/24
-3.02 (-21.74%)
since 12/28/23
52-Week
3.80 +186.05%
on 10/25/23
20.00 -45.65%
on 04/17/23
-0.33 (-2.96%)
since 03/28/23

Most Recent Stories

More News
Curis: Q4 Earnings Snapshot

Curis: Q4 Earnings Snapshot

CRIS : 10.87 (unch)
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 10.87 (unch)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 10.87 (unch)
Curis to Present at Upcoming Healthcare Conferences in September

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4...

CRIS : 10.87 (unch)
Curis: Q2 Earnings Snapshot

Curis: Q2 Earnings Snapshot

CRIS : 10.87 (unch)
Curis Provides Second Quarter 2023 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 10.87 (unch)
Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4...

CRIS : 10.87 (unch)
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

/PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple...

CRIS : 10.87 (unch)
Curis Announces $15.1 Million Registered Direct Offering

/PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK)...

CRIS : 10.87 (unch)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

CRIS : 10.87 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 11.62
2nd Resistance Point 11.28
1st Resistance Point 11.08
Last Price 10.87
1st Support Level 10.54
2nd Support Level 10.20
3rd Support Level 10.00

See More

52-Week High 20.00
Fibonacci 61.8% 13.81
Fibonacci 50% 11.90
Last Price 10.87
Fibonacci 38.2% 9.99
52-Week Low 3.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar